Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to show a fall in quarterly revenue when it reports results on May 13 for the period ending March 31 2025
The West Chester Pennsylvania-based company is expected to report a 34.4% decrease in revenue to $2.511 million from $3.83 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Verrica Pharmaceuticals Inc is for a loss of 10 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $3.00, above its last closing price of $0.42.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.28 | -0.26 | -0.24 | Beat | 8.6 |
Sep. 30 2024 | -0.39 | -0.37 | -0.49 | Missed | -33.5 |
Jun. 30 2024 | -0.43 | -0.42 | -0.37 | Beat | 12.9 |
Mar. 31 2024 | -0.46 | -0.40 | -0.44 | Missed | -10.9 |
Dec. 31 2023 | -0.53 | -0.53 | -0.53 | Met | -0.4 |
Sep. 30 2023 | -0.35 | -0.36 | -0.54 | Missed | -49.5 |
Jun. 30 2023 | -0.22 | -0.21 | -0.24 | Missed | -14.2 |
Mar. 31 2023 | -0.18 | -0.19 | -0.15 | Beat | 21.1 |
This summary was machine generated May 9 at 15:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。